 | • レポートコード：MRC308GR09513 • 出版社/出版日：GlobalInfoResearch / 2023年8月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界の血管運動症状用治療の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の血管運動症状用治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– 血管運動症状用治療の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
血管運動症状用治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・ホルモン療法、非ホルモン療法、その他
用途別セグメント
・診療所、病院、その他
主要な市場プレーヤー
・Bayer AG、Fervent Pharmaceuticals, LLC、Astellas Pharma Inc.、Frazier Healthcare Partners、Mitsubishi Tanabe Pharma Corporation、Eli Lilly and Company、AbbVie Inc.、AMAG Pharmaceuticals Inc.、Emcure Pharmaceuticals Limited、Merck & Co., Inc.、Novartis AG、Novo Nordisk A/S、Pfizer Inc.、Teva Pharmaceutical Industries Ltd.
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、血管運動症状用治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な血管運動症状用治療メーカーの企業概要、2019年～2022年までの血管運動症状用治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な血管運動症状用治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別血管運動症状用治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの血管運動症状用治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での血管運動症状用治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および血管運動症状用治療の産業チェーンを掲載しています。
・第14、15章では、血管運動症状用治療の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– 血管運動症状用治療の概要
– 種類別分析（2018年vs2022年vs2029年）：ホルモン療法、非ホルモン療法、その他
– 用途別分析（2018年vs2022年vs2029年）：診療所、病院、その他
– 世界の血管運動症状用治療市場規模・予測
– 世界の血管運動症状用治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Bayer AG、Fervent Pharmaceuticals, LLC、Astellas Pharma Inc.、Frazier Healthcare Partners、Mitsubishi Tanabe Pharma Corporation、Eli Lilly and Company、AbbVie Inc.、AMAG Pharmaceuticals Inc.、Emcure Pharmaceuticals Limited、Merck & Co., Inc.、Novartis AG、Novo Nordisk A/S、Pfizer Inc.、Teva Pharmaceutical Industries Ltd.
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：ホルモン療法、非ホルモン療法、その他
・用途別分析2018年-2029年：診療所、病院、その他
・血管運動症状用治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・血管運動症状用治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・血管運動症状用治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・血管運動症状用治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・血管運動症状用治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Vasomotor Symptoms Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Vasomotor Symptoms Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Hormonal Therapies
1.3.3 Non-Hormonal Therapies
1.3.4 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Vasomotor Symptoms Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Clinic
1.4.3 Hospital
1.4.4 Others
1.5 Global Vasomotor Symptoms Treatment Market Size & Forecast
1.5.1 Global Vasomotor Symptoms Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Vasomotor Symptoms Treatment Sales Quantity (2018-2029)
1.5.3 Global Vasomotor Symptoms Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Bayer AG
2.1.1 Bayer AG Details
2.1.2 Bayer AG Major Business
2.1.3 Bayer AG Vasomotor Symptoms Treatment Product and Services
2.1.4 Bayer AG Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer AG Recent Developments/Updates
2.2 Fervent Pharmaceuticals, LLC
2.2.1 Fervent Pharmaceuticals, LLC Details
2.2.2 Fervent Pharmaceuticals, LLC Major Business
2.2.3 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product and Services
2.2.4 Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Fervent Pharmaceuticals, LLC Recent Developments/Updates
2.3 Astellas Pharma Inc.
2.3.1 Astellas Pharma Inc. Details
2.3.2 Astellas Pharma Inc. Major Business
2.3.3 Astellas Pharma Inc. Vasomotor Symptoms Treatment Product and Services
2.3.4 Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Astellas Pharma Inc. Recent Developments/Updates
2.4 Frazier Healthcare Partners
2.4.1 Frazier Healthcare Partners Details
2.4.2 Frazier Healthcare Partners Major Business
2.4.3 Frazier Healthcare Partners Vasomotor Symptoms Treatment Product and Services
2.4.4 Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Frazier Healthcare Partners Recent Developments/Updates
2.5 Mitsubishi Tanabe Pharma Corporation
2.5.1 Mitsubishi Tanabe Pharma Corporation Details
2.5.2 Mitsubishi Tanabe Pharma Corporation Major Business
2.5.3 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product and Services
2.5.4 Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates
2.6 Eli Lilly and Company
2.6.1 Eli Lilly and Company Details
2.6.2 Eli Lilly and Company Major Business
2.6.3 Eli Lilly and Company Vasomotor Symptoms Treatment Product and Services
2.6.4 Eli Lilly and Company Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Eli Lilly and Company Recent Developments/Updates
2.7 AbbVie Inc.
2.7.1 AbbVie Inc. Details
2.7.2 AbbVie Inc. Major Business
2.7.3 AbbVie Inc. Vasomotor Symptoms Treatment Product and Services
2.7.4 AbbVie Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 AbbVie Inc. Recent Developments/Updates
2.8 AMAG Pharmaceuticals Inc.
2.8.1 AMAG Pharmaceuticals Inc. Details
2.8.2 AMAG Pharmaceuticals Inc. Major Business
2.8.3 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product and Services
2.8.4 AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 AMAG Pharmaceuticals Inc. Recent Developments/Updates
2.9 Emcure Pharmaceuticals Limited
2.9.1 Emcure Pharmaceuticals Limited Details
2.9.2 Emcure Pharmaceuticals Limited Major Business
2.9.3 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product and Services
2.9.4 Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Emcure Pharmaceuticals Limited Recent Developments/Updates
2.10 Merck & Co., Inc.
2.10.1 Merck & Co., Inc. Details
2.10.2 Merck & Co., Inc. Major Business
2.10.3 Merck & Co., Inc. Vasomotor Symptoms Treatment Product and Services
2.10.4 Merck & Co., Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Merck & Co., Inc. Recent Developments/Updates
2.11 Novartis AG
2.11.1 Novartis AG Details
2.11.2 Novartis AG Major Business
2.11.3 Novartis AG Vasomotor Symptoms Treatment Product and Services
2.11.4 Novartis AG Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Novartis AG Recent Developments/Updates
2.12 Novo Nordisk A/S
2.12.1 Novo Nordisk A/S Details
2.12.2 Novo Nordisk A/S Major Business
2.12.3 Novo Nordisk A/S Vasomotor Symptoms Treatment Product and Services
2.12.4 Novo Nordisk A/S Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Novo Nordisk A/S Recent Developments/Updates
2.13 Pfizer Inc.
2.13.1 Pfizer Inc. Details
2.13.2 Pfizer Inc. Major Business
2.13.3 Pfizer Inc. Vasomotor Symptoms Treatment Product and Services
2.13.4 Pfizer Inc. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Pfizer Inc. Recent Developments/Updates
2.14 Teva Pharmaceutical Industries Ltd.
2.14.1 Teva Pharmaceutical Industries Ltd. Details
2.14.2 Teva Pharmaceutical Industries Ltd. Major Business
2.14.3 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product and Services
2.14.4 Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
3 Competitive Environment: Vasomotor Symptoms Treatment by Manufacturer
3.1 Global Vasomotor Symptoms Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Vasomotor Symptoms Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Vasomotor Symptoms Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Vasomotor Symptoms Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Vasomotor Symptoms Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Vasomotor Symptoms Treatment Manufacturer Market Share in 2022
3.5 Vasomotor Symptoms Treatment Market: Overall Company Footprint Analysis
3.5.1 Vasomotor Symptoms Treatment Market: Region Footprint
3.5.2 Vasomotor Symptoms Treatment Market: Company Product Type Footprint
3.5.3 Vasomotor Symptoms Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Vasomotor Symptoms Treatment Market Size by Region
4.1.1 Global Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Vasomotor Symptoms Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Vasomotor Symptoms Treatment Average Price by Region (2018-2029)
4.2 North America Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.3 Europe Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.5 South America Vasomotor Symptoms Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Vasomotor Symptoms Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
5.2 Global Vasomotor Symptoms Treatment Consumption Value by Type (2018-2029)
5.3 Global Vasomotor Symptoms Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
6.2 Global Vasomotor Symptoms Treatment Consumption Value by Application (2018-2029)
6.3 Global Vasomotor Symptoms Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
7.2 North America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
7.3 North America Vasomotor Symptoms Treatment Market Size by Country
7.3.1 North America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Vasomotor Symptoms Treatment Market Size by Country
8.3.1 Europe Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Vasomotor Symptoms Treatment Market Size by Region
9.3.1 Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Vasomotor Symptoms Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
10.2 South America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
10.3 South America Vasomotor Symptoms Treatment Market Size by Country
10.3.1 South America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Vasomotor Symptoms Treatment Market Size by Country
11.3.1 Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Vasomotor Symptoms Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Vasomotor Symptoms Treatment Market Drivers
12.2 Vasomotor Symptoms Treatment Market Restraints
12.3 Vasomotor Symptoms Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Vasomotor Symptoms Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Vasomotor Symptoms Treatment
13.3 Vasomotor Symptoms Treatment Production Process
13.4 Vasomotor Symptoms Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Vasomotor Symptoms Treatment Typical Distributors
14.3 Vasomotor Symptoms Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Vasomotor Symptoms Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Vasomotor Symptoms Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 4. Bayer AG Major Business
Table 5. Bayer AG Vasomotor Symptoms Treatment Product and Services
Table 6. Bayer AG Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Bayer AG Recent Developments/Updates
Table 8. Fervent Pharmaceuticals, LLC Basic Information, Manufacturing Base and Competitors
Table 9. Fervent Pharmaceuticals, LLC Major Business
Table 10. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Product and Services
Table 11. Fervent Pharmaceuticals, LLC Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Fervent Pharmaceuticals, LLC Recent Developments/Updates
Table 13. Astellas Pharma Inc. Basic Information, Manufacturing Base and Competitors
Table 14. Astellas Pharma Inc. Major Business
Table 15. Astellas Pharma Inc. Vasomotor Symptoms Treatment Product and Services
Table 16. Astellas Pharma Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Astellas Pharma Inc. Recent Developments/Updates
Table 18. Frazier Healthcare Partners Basic Information, Manufacturing Base and Competitors
Table 19. Frazier Healthcare Partners Major Business
Table 20. Frazier Healthcare Partners Vasomotor Symptoms Treatment Product and Services
Table 21. Frazier Healthcare Partners Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Frazier Healthcare Partners Recent Developments/Updates
Table 23. Mitsubishi Tanabe Pharma Corporation Basic Information, Manufacturing Base and Competitors
Table 24. Mitsubishi Tanabe Pharma Corporation Major Business
Table 25. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Product and Services
Table 26. Mitsubishi Tanabe Pharma Corporation Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Mitsubishi Tanabe Pharma Corporation Recent Developments/Updates
Table 28. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 29. Eli Lilly and Company Major Business
Table 30. Eli Lilly and Company Vasomotor Symptoms Treatment Product and Services
Table 31. Eli Lilly and Company Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Eli Lilly and Company Recent Developments/Updates
Table 33. AbbVie Inc. Basic Information, Manufacturing Base and Competitors
Table 34. AbbVie Inc. Major Business
Table 35. AbbVie Inc. Vasomotor Symptoms Treatment Product and Services
Table 36. AbbVie Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. AbbVie Inc. Recent Developments/Updates
Table 38. AMAG Pharmaceuticals Inc. Basic Information, Manufacturing Base and Competitors
Table 39. AMAG Pharmaceuticals Inc. Major Business
Table 40. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Product and Services
Table 41. AMAG Pharmaceuticals Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. AMAG Pharmaceuticals Inc. Recent Developments/Updates
Table 43. Emcure Pharmaceuticals Limited Basic Information, Manufacturing Base and Competitors
Table 44. Emcure Pharmaceuticals Limited Major Business
Table 45. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Product and Services
Table 46. Emcure Pharmaceuticals Limited Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Emcure Pharmaceuticals Limited Recent Developments/Updates
Table 48. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 49. Merck & Co., Inc. Major Business
Table 50. Merck & Co., Inc. Vasomotor Symptoms Treatment Product and Services
Table 51. Merck & Co., Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Merck & Co., Inc. Recent Developments/Updates
Table 53. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 54. Novartis AG Major Business
Table 55. Novartis AG Vasomotor Symptoms Treatment Product and Services
Table 56. Novartis AG Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Novartis AG Recent Developments/Updates
Table 58. Novo Nordisk A/S Basic Information, Manufacturing Base and Competitors
Table 59. Novo Nordisk A/S Major Business
Table 60. Novo Nordisk A/S Vasomotor Symptoms Treatment Product and Services
Table 61. Novo Nordisk A/S Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Novo Nordisk A/S Recent Developments/Updates
Table 63. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 64. Pfizer Inc. Major Business
Table 65. Pfizer Inc. Vasomotor Symptoms Treatment Product and Services
Table 66. Pfizer Inc. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Pfizer Inc. Recent Developments/Updates
Table 68. Teva Pharmaceutical Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 69. Teva Pharmaceutical Industries Ltd. Major Business
Table 70. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Product and Services
Table 71. Teva Pharmaceutical Industries Ltd. Vasomotor Symptoms Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Teva Pharmaceutical Industries Ltd. Recent Developments/Updates
Table 73. Global Vasomotor Symptoms Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 74. Global Vasomotor Symptoms Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 75. Global Vasomotor Symptoms Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 76. Market Position of Manufacturers in Vasomotor Symptoms Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 77. Head Office and Vasomotor Symptoms Treatment Production Site of Key Manufacturer
Table 78. Vasomotor Symptoms Treatment Market: Company Product Type Footprint
Table 79. Vasomotor Symptoms Treatment Market: Company Product Application Footprint
Table 80. Vasomotor Symptoms Treatment New Market Entrants and Barriers to Market Entry
Table 81. Vasomotor Symptoms Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 82. Global Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 83. Global Vasomotor Symptoms Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 84. Global Vasomotor Symptoms Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 85. Global Vasomotor Symptoms Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 86. Global Vasomotor Symptoms Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 87. Global Vasomotor Symptoms Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 88. Global Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Global Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Global Vasomotor Symptoms Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Global Vasomotor Symptoms Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Global Vasomotor Symptoms Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 93. Global Vasomotor Symptoms Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 94. Global Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Global Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Global Vasomotor Symptoms Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 97. Global Vasomotor Symptoms Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 98. Global Vasomotor Symptoms Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 99. Global Vasomotor Symptoms Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 100. North America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 101. North America Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 102. North America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 103. North America Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 104. North America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 105. North America Vasomotor Symptoms Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 106. North America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 107. North America Vasomotor Symptoms Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Europe Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Europe Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Europe Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Europe Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Europe Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 113. Europe Vasomotor Symptoms Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 114. Europe Vasomotor Symptoms Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe Vasomotor Symptoms Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 117. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 118. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 119. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 120. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 121. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 122. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 123. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 124. South America Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 125. South America Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 126. South America Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 127. South America Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 128. South America Vasomotor Symptoms Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 129. South America Vasomotor Symptoms Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 130. South America Vasomotor Symptoms Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 131. South America Vasomotor Symptoms Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 132. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 133. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 134. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 135. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 136. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 137. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 138. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 139. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 140. Vasomotor Symptoms Treatment Raw Material
Table 141. Key Manufacturers of Vasomotor Symptoms Treatment Raw Materials
Table 142. Vasomotor Symptoms Treatment Typical Distributors
Table 143. Vasomotor Symptoms Treatment Typical Customers
List of Figures
Figure 1. Vasomotor Symptoms Treatment Picture
Figure 2. Global Vasomotor Symptoms Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Type in 2022
Figure 4. Hormonal Therapies Examples
Figure 5. Non-Hormonal Therapies Examples
Figure 6. Others Examples
Figure 7. Global Vasomotor Symptoms Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 8. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Application in 2022
Figure 9. Clinic Examples
Figure 10. Hospital Examples
Figure 11. Others Examples
Figure 12. Global Vasomotor Symptoms Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Vasomotor Symptoms Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Vasomotor Symptoms Treatment Sales Quantity (2018-2029) & (K Units)
Figure 15. Global Vasomotor Symptoms Treatment Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Vasomotor Symptoms Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Vasomotor Symptoms Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Vasomotor Symptoms Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Vasomotor Symptoms Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Vasomotor Symptoms Treatment Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Vasomotor Symptoms Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Vasomotor Symptoms Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Vasomotor Symptoms Treatment Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Vasomotor Symptoms Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Vasomotor Symptoms Treatment Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Vasomotor Symptoms Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Vasomotor Symptoms Treatment Consumption Value Market Share by Region (2018-2029)
Figure 54. China Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Vasomotor Symptoms Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Vasomotor Symptoms Treatment Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Vasomotor Symptoms Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Vasomotor Symptoms Treatment Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Vasomotor Symptoms Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Vasomotor Symptoms Treatment Market Drivers
Figure 75. Vasomotor Symptoms Treatment Market Restraints
Figure 76. Vasomotor Symptoms Treatment Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Vasomotor Symptoms Treatment in 2022
Figure 79. Manufacturing Process Analysis of Vasomotor Symptoms Treatment
Figure 80. Vasomotor Symptoms Treatment Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source